金城医药：拟转让药品生产技术及上市许可持有人权益

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and market authorization rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of RMB 50 million [1] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd, is involved in the transaction [1] - The product being transferred is "Progesterone Vaginal Soft Capsules," marketed under the name "Langyigeng Baofen" [1] - The agreed transfer fee of RMB 50 million has been determined based on the actual value of the product rights and market conditions [1]